Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial.

MLA

Mahomed, Sharana, et al. “Safety and Pharmacokinetics of Escalating Doses of Neutralising Monoclonal Antibody CAP256V2LS Administered with and without VRC07-523LS in HIV-Negative Women in South Africa (CAPRISA 012B): A Phase 1, Dose-Escalation, Randomised Controlled Trial.” The Lancet. HIV, vol. 10, no. 4, Apr. 2023, pp. e230–43. EBSCOhost, https://doi.org/10.1016/S2352-3018(23)00003-6.

APA

Mahomed, S., Garrett, N., Capparelli, E. V., Osman, F., Mkhize, N. N., Harkoo, I., Gengiah, T. N., Mansoor, L. E., Baxter, C., Archary, D., Yende-Zuma, N., Samsunder, N., Carlton, K., Narpala, S., McDermott, A. B., Doria-Rose, N. A., Moore, P. L., Morris, L., Abdool Karim, Q., … Abdool Karim, S. S. (2023). Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial. The Lancet. HIV, 10(4), e230–e243. https://doi.org/10.1016/S2352-3018(23)00003-6

Chicago

Mahomed, Sharana, Nigel Garrett, Edmund V Capparelli, Farzana Osman, Nonhlanhla N Mkhize, Ishana Harkoo, Tanuja N Gengiah, et al. 2023. “Safety and Pharmacokinetics of Escalating Doses of Neutralising Monoclonal Antibody CAP256V2LS Administered with and without VRC07-523LS in HIV-Negative Women in South Africa (CAPRISA 012B): A Phase 1, Dose-Escalation, Randomised Controlled Trial.” The Lancet. HIV 10 (4): e230–43. doi:10.1016/S2352-3018(23)00003-6.